VENUS REMEDIES
Quarterly Results Analysis [Sep2024]
VENUS REMEDIES Quarterly Results
Consolidated | Sep2024 UnAudited |
Jun2024 UnAudited |
Mar2024 UnAudited |
Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
Mar2023 UnAudited |
Dec2022 UnAudited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹167 Cr | ₹109 Cr | ₹195 Cr | ₹143 Cr | ₹168 Cr | ₹95 Cr | ₹156 Cr | ₹117 Cr |
Expenses | ₹163 Cr | ₹97 Cr | ₹176 Cr | ₹131 Cr | ₹150 Cr | ₹85 Cr | ₹131 Cr | ₹109 Cr |
Operating Income | ₹5 Cr | ₹11 Cr | ₹19 Cr | ₹12 Cr | ₹18 Cr | ₹10 Cr | ₹25 Cr | ₹8 Cr |
Other Income | ₹11 Cr | ₹2 Cr | ₹4 Cr | ₹2 Cr | ₹3 Cr | ₹2 Cr | ₹3 Cr | ₹4 Cr |
Interest | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
Depreciation | ₹6 Cr | ₹6 Cr | ₹6 Cr | ₹7 Cr | ₹6 Cr | ₹8 Cr | ₹8 Cr | ₹7 Cr |
Profit Before Tax | ₹9 Cr | ₹7 Cr | ₹17 Cr | ₹8 Cr | ₹14 Cr | ₹5 Cr | ₹20 Cr | ₹5 Cr |
Profit After Tax | ₹4 Cr | ₹1 Cr | ₹11 Cr | ₹7 Cr | ₹10 Cr | ₹1 Cr | ₹11 Cr | ₹3 Cr |
EPS | ₹2.63 | ₹0.91 | ₹7.86 | ₹5.12 | ₹7.43 | ₹0.88 | ₹8.27 | ₹2.46 |
Industry Peers & Returns | 1W | 1M | 1Y |
VENUS REMEDIES | 6.5% | 2.1% | -21.1% |
SUN PHARMACEUTICAL INDUSTRIES | 2.7% | -2.4% | 49.5% |
CIPLA | 1% | 6.4% | 28.7% |
DR REDDYS LABORATORIES | 1% | -2.3% | 6% |
ZYDUS LIFESCIENCES | 2.4% | -1.1% | 53.4% |
DIVIS LABORATORIES | 2.9% | 6.2% | 64.2% |
MANKIND PHARMA | 1.2% | -0.5% | 35.1% |
TORRENT PHARMACEUTICALS | 3.5% | 6.4% | 60% |
LUPIN | 1.7% | -4.1% | 64.7% |
VENUS REMEDIES Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | 54.18 % |
Y-o-Y | -0.16 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Sep2024 | ₹167 Cr | 54.18 | |
Jun2024 | ₹109 Cr | -44.35 | |
Mar2024 | ₹195 Cr | 36.08 | |
Dec2023 | ₹143 Cr | -14.49 | |
Sep2023 | ₹168 Cr | 76.27 | |
Jun2023 | ₹95 Cr | -38.87 | |
Mar2023 | ₹156 Cr | 33.14 | |
Dec2022 | ₹117 Cr | - |
VENUS REMEDIES Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | -56.39 % |
Y-o-Y | -72.34 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Sep2024 | ₹5 Cr | -56.39 | |
Jun2024 | ₹11 Cr | -42.20 | |
Mar2024 | ₹19 Cr | 61.79 | |
Dec2023 | ₹12 Cr | -32.17 | |
Sep2023 | ₹18 Cr | 70.67 | |
Jun2023 | ₹10 Cr | -57.74 | |
Mar2023 | ₹25 Cr | 203.83 | |
Dec2022 | ₹8 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | -71.75 % |
Y-o-Y | -72.31 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Sep2024 | 2.93% | -71.75 | |
Jun2024 | 10.37% | 3.91 | |
Mar2024 | 9.98% | 18.95 | |
Dec2023 | 8.39% | -20.70 | |
Sep2023 | 10.58% | -3.20 | |
Jun2023 | 10.93% | -30.87 | |
Mar2023 | 15.81% | 128.14 | |
Dec2022 | 6.93% | - |
VENUS REMEDIES Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | 187.70 % |
Y-o-Y | -64.69 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Sep2024 | ₹4 Cr | 187.70 | |
Jun2024 | ₹1 Cr | -88.39 | |
Mar2024 | ₹11 Cr | 53.43 | |
Dec2023 | ₹7 Cr | -31.09 | |
Sep2023 | ₹10 Cr | 742.37 | |
Jun2023 | ₹1 Cr | -89.33 | |
Mar2023 | ₹11 Cr | 236.17 | |
Dec2022 | ₹3 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | 87.50 % |
Y-o-Y | -64.59 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Sep2024 | 2.1 % | 87.50 | |
Jun2024 | 1.12 % | -79.22 | |
Mar2024 | 5.39 % | 12.76 | |
Dec2023 | 4.78 % | -19.39 | |
Sep2023 | 5.93 % | 378.23 | |
Jun2023 | 1.24 % | -82.56 | |
Mar2023 | 7.11 % | 153.02 | |
Dec2022 | 2.81 % | - |
VENUS REMEDIES Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | 189.01 % |
Y-o-Y | -64.60 % |
Quarters | EPS | % Change | |
---|---|---|---|
Sep2024 | ₹2.63 | 189.01 | |
Jun2024 | ₹0.91 | -88.42 | |
Mar2024 | ₹7.86 | 53.52 | |
Dec2023 | ₹5.12 | -31.09 | |
Sep2023 | ₹7.43 | 744.32 | |
Jun2023 | ₹0.88 | -89.36 | |
Mar2023 | ₹8.27 | 236.18 | |
Dec2022 | ₹2.46 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs MANKIND PHARMA LTD